The growth of prostate cancer cells is relevant to the androgen level; therefore, androgen deprivation therapy (ADT), a treatment to reduce androgen levels and/or block androgen receptor activity, has been introduced to most early-stage prostate cancer patients [4]. This evidence concerns the gene AR and prostate carcinoma.